Biotech Values

[WID]

OPTR: Prime Acquisition Target

I just read this article from Seeking Alpha where the author say OPTR may be a prime acquisition target and they compare Fidaxomicin vs. Vancocin head-to-head.

OPTR will have the FDA panel to review Fidaxomicin for the treatment of Clostridium difficile infection on 4/5/11.

According to Seeking Alpha, it seems that the clinical cure rates between fidaxomicin and vancomycin were similar, with slightly better results from fidaxomicin. Fidaxomicin significantly reduced the risk of recurrence among CDI patients. Fidaxomicin demonstrated a statistically significant higher global cure rate, defined as curing the patient at the end of treatment without recurrence.

If these are true, OPTR will have a good chance to get positive review from the panel.

If anyone of you has different opinions about this, please share!

Thanks a lot!
WID